Navigation Links
PharmaNet Development Group Gives Notice of Anticipated Fundamental Change and Merger to Holders of Its Convertible Notes
Date:3/17/2009

s class action lawsuit, the impact of ongoing tax audits, PharmaNet's ability to generate new client contracts and maintain its existing clients' contracts, its evaluation of its backlog and the potential cancellation of contracts, the possibility PharmaNet under-priced its contracts or overrun cost estimates and the effect on PharmaNet's financial results by failure to receive approval for change orders and by delays in documenting change orders, its ability to implement its business strategy, international economic, political and other risks that could negatively affect its results of operations or financial position, changes in outsourcing trends and regulatory requirements affecting the branded pharmaceutical, biotechnology, generic drug and medical device industries, the reduction of expenditures by branded pharmaceutical, biotechnology, generic drug or medical device companies, actions or inspections by regulatory authorities and the impact on PharmaNet's clients' decisions to not award future contracts to PharmaNet or to cancel existing contracts, the impact of healthcare reform, the fact that one or a limited number of clients may account for a large percentage of PharmaNet revenues, the incurrence of significant taxes to repatriate funds, the fluctuation of PharmaNet operating results from period to period, PharmaNet assessment of PharmaNet goodwill valuation, the impact of foreign currency fluctuations, tax law changes in Canada or in other foreign jurisdictions, investigations by governmental authorities regarding PharmaNet inter-company transfer pricing policies or changes to their laws in a manner that could increase PharmaNet effective tax rate or otherwise harm PharmaNet business, PharmaNet lack of the resources needed to compete effectively with larger competitors, PharmaNet ability to continue to develop new assay methods for PharmaNet analytical applications, or if PharmaNet current assay methods are incorrect, PharmaNet ability to compete with oth
'/>"/>
SOURCE PharmaNet Development Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PharmaNet Development Group, Inc. Expands Latin America Operations with Opening of Brazil Office
2. An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share
3. PharmaNet Development Group Agrees to be Acquired by JLL Partners
4. PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting
5. Med Discovery and Laborium Biopharma Extend Their Development Partnership to Include Mammalian Cell Culture Processes and Clinical Manufacturing for All Products in Med Discovery's Portfolio
6. Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
7. Covance Increases Early Clinical Footprint in Europe with Acquisition of Swiss-Based Early Clinical Development Site
8. PAREXEL Expert to Address Value of Incorporating Asia Into Global Clinical Development at BioMedical Asia 2009
9. AMDL, Inc. Enters Into Collaboration Agreement to Advance Development of Its AMDL DR-70 (FDP) Cancer Test
10. Dr. James Cai Joins aTyr Pharma to Drive Clinical Development in Asia
11. AMPAC Fine Chemicals Announces the Inauguration of the New cGMP Continuous Processing Development Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Diagenode, Inc., a leading global provider ... complete solutions for epigenetics research, recently launched a ... need for manual processing. The new ChIPettor System ... histones or transcription factors and a semi-automated pipette ...
(Date:1/22/2015)... Mass. , Jan. 22, 2015   GenoSpace , a ... of tools to enable the broad use of genomic, imaging ... announced the appointment of Michelle Munson , CEO of ... director. Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
(Date:12/24/2014)... and NEW YORK , Dec. 24, ... company advancing patient care in critical areas, announced the closing ... stock, and warrants to purchase up to an aggregate 3,500,000 ... per share and $.01 per warrant.  The warrants have a ...
(Date:12/24/2014)... Missouri (PRWEB) December 23, 2014 GMO corn ... company, Syngenta, are in the process of being consolidated in ... is In Re: Syngenta AG MIR 162 Corn Litigation, MDL ... of Kansas. , Management of the Syngenta GMO corn multidistrict ...
Breaking Biology Technology:Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... , , , ... Held) today announced that Chief Executive Officer Dr. Allan E. Rubenstein ... September. The first presentation will take place on September 11th, ... Annual Healthcare Conference in New York, New York. The second ...
... ... by Principal and Founder, David A. Dodd. , ... Beaufort, SC (Vocus) - The formation of RiversEdge BioVentures LLC is announced ... Mr. Dodd achieved a highly distinguished career, serving in executive positions in several major pharmaceutical ...
... , , ABBOTT PARK, ... ABT ) announced today a definitive agreement to acquire the ... of devices for minimally invasive repair of cardiac mitral valves. ... of non-surgical treatment for structural heart disease, in which physicians use ...
Cached Biology Technology:NexGenix Pharmaceuticals to Present at Two Industry Conferences: Rodman & Renshaw 11th Annual Healthcare Conference and Life Sciences Summit 2009 2RiversEdge BioVentures LLC to Provide Advisory and Investment Services in Life Sciences 2Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology 2Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology 3Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology 4
(Date:12/17/2014)... Dec. 15, 2014 The Defense Logistics Agency is ... and prevent counterfeit microcircuits from entering into its supply ... in-house microcircuit anti-counterfeit initiative dubbed DNA marking. The capability ... their reliability throughout the supply chain. The new quality ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a technology ... measures the overall facial feature of a person such ...
(Date:12/10/2014)... been here before: you desperately need to sign into your online ... answer to your secret question. What,s your dog,s birthday? Who was ... , a digital infrastructure security company, launches the app ... with usernames, passwords and PINs – 1U TM . ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... carried out by scientists at the Georgia Institute of Technology ... how cells stick to each other and to other bodily ... and organs. It,s thought that abnormalities in their ability to ... of disorders, including cardiovascular disease and cancer. The study,s ...
... first demonstrated by the ancient Romans, researchers at ... a novel, ultra-sensitive tool for chemical, DNA, and ... spectroscopy sensing, for the first time, becomes colorimetric ... color photography," explained Logan Liu, an assistant professor ...
... present in the gut can affect the severity of ... an international study led by Professor Wei Jia at ... research group of Professor Jeremy Nicholson at Imperial College ... hospitalised with kidney disease brought on by supplies of ...
Cached Biology News:Why cells stick: Phenomenon extends longevity of bonds between cells 2Why cells stick: Phenomenon extends longevity of bonds between cells 3The world's most sensitive plasmon resonance sensor inspired by ancient Roman cup 2The world's most sensitive plasmon resonance sensor inspired by ancient Roman cup 3Gut microbes could determine the severity of melamine-induced kidney disease 2
Recombinant Human PTP1B (aa 2-321), CF...
Rat CXCL7/Thymus Chemokine-1 DuoSet Economy Pack, 45 Plate...
X-Gal, 1 g. 5-Bromo-4-chloro-3-indolyl-b-d-galactoside.Histochemical substrate for b-galactosidase, used in blue/white screening.Store at -20 C. Protect from moisture. Category: Nucleotides & Enzymes...
Recombinant Rat Fas Ligand/TNFSF6...
Biology Products: